Biomet progresses in Japan; CardioDynamics moves into profit
This article was originally published in Clinica
Orthopaedic company Biomet's sales increase was led by "strong, balanced growth in its reconstructive, fixation and spinal product lines", the company says. Excluding foreign currency effects, growth in the quarter was 21%. The company, of Warsaw, Indiana, is continuing to make progress in establishing direct sales operations in Japan. However, its sales were hit by an estimated $1.7 million reduction in product purchases by its former distribution organisation in Japan. "However, we believe that Biomet's long-term prospects in Japan will improve as a result of these initiatives," said Dane Miller, Biomet's president and CEO. The company's reconstructive device division saw sales rise by 16% to $161 million, led by demand for total knee implants. Sales in the fixation division increased by 16% to $54 million, driven by its electrical stimulation systems. Spinal sales were $27 million, a 107% increase, while sales of other products were up 14% to $30 million.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.